<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098241</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AB351</org_study_id>
    <secondary_id>RAD/Certican</secondary_id>
    <nct_id>NCT00098241</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Certican in Pediatric de Novo Renal Transplant Patients</brief_title>
  <official_title>Multicenter Trial of the Safety &amp; Efficacy of Certican in Pediatric de Novo Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican)
      administered to pediatric renal transplant recipients, and to provide additional safety data.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability at 6 and 12 Months as measured by adverse events, laboratory abnormalities and infections.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy at 6 and 12 Months as measured by rejection, graft loss, death and loss to follow up.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certican</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients no more than 16 years of age.

          -  Patients receiving a primary cadaveric or non-HLA identical living donor (related or
             unrelated) renal transplant.

          -  The graft must be functional within 48 hours post transplantation.

        Exclusion Criteria:

          -  Cold ischemia time greater than 40 hours.

          -  Patients who are recipients of multiple solid organ transplants, including dual and en
             bloc kidneys, or who have previously received transplanted organs.

          -  Patients with panel reactive T cell antibodies of 50 % or higher at the last
             assessment before transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbus Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dienst Pediatrie UZ Gasthuisberg, Herestraat 49</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14657</url>
    <description>Results for CRAD001AB351 from Novartis Clinical Trials Website</description>
  </link>
  <results_reference>
    <citation>Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8. Review.</citation>
    <PMID>11583941</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2004</study_first_submitted>
  <study_first_submitted_qc>December 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2004</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>renal</keyword>
  <keyword>transplant recipients</keyword>
  <keyword>de novo</keyword>
  <keyword>De novo renal pediatric transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

